Lupin Limited has informed the Exchange about U.S. FDA has conducted an inspection at Company's manufacturing facility located at Goa, India.
LUPIN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 1.9 pts less than Nifty Midcap 150 and 1.4 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Lupin has disclosed that the U.S. FDA carried out an inspection at its manufacturing facility in Goa, India. The company has shared this information with the stock exchange as a routine update. The announcement does not mention any specific observations, warnings, or outcomes from the inspection at this stage. The Goa plant is one of Lupin's key manufacturing sites supplying formulations to the U.S. market.
FDA inspections are routine, but investors should watch for follow-up disclosures regarding the inspection outcome (such as Form 483 observations or an EIR classification), as adverse findings could affect U.S. drug approvals and supply from this facility, potentially impacting revenue.